Oxford Biomedica (LON:OXB) Announces Earnings Results

Oxford Biomedica (LON:OXB) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%.

Oxford Biomedica Stock Down 2.0%

Shares of Oxford Biomedica stock traded down GBX 10 during trading on Wednesday, hitting GBX 483. 650,515 shares of the stock traded hands, compared to its average volume of 1,106,726. The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 162.16. The stock’s fifty day simple moving average is GBX 515.68 and its 200 day simple moving average is GBX 577.12. The firm has a market cap of £584.66 million, a P/E ratio of -17.94 and a beta of 1.09. Oxford Biomedica has a 52-week low of GBX 420 and a 52-week high of GBX 952.

Analysts Set New Price Targets

A number of research firms recently commented on OXB. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 595 price target on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Jefferies Financial Group reissued a “buy” rating and issued a GBX 8.27 price objective on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Finally, Royal Bank Of Canada restated an “outperform” rating and set a GBX 900 target price on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of GBX 580.85.

Key Headlines Impacting Oxford Biomedica

Here are the key news stories impacting Oxford Biomedica this week:

• Positive Sentiment: Client wins and pipeline visibility improved. Oxford Biomedica reported 17 new clients, described as a record level of commercial wins. Management said the stronger client pipeline improves revenue visibility and supports its existing full-year outlook. OXB wins 17 new clients as its expansion gathers pace
• Positive Sentiment: First-half revenue growth and strategic expansion were encouraging. H1 revenue reached £80.2 million, representing 9% growth, while Oxford Biomedica maintained its FY2026 guidance. The company is also expanding its global quality infrastructure through Veeva Quality Cloud, which could support operational scalability and compliance as its customer base grows. Oxford Biomedica delivers solid H1 growth, record commercial wins
• Neutral Sentiment: Veeva’s customer announcement signals broader adoption of its technology, but the financial benefit to OXB is indirect. Oxford Biomedica’s use of Veeva Quality Cloud may improve quality processes, although the announcement does not materially change near-term revenue expectations. Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud
• Negative Sentiment: Losses remain the main investor concern. Oxford Biomedica reported quarterly EPS of negative 30.39 pence, a negative 17.85% net margin and negative 48.56% return on equity. The first-half loss widened even as revenue increased, highlighting ongoing profitability and execution risks. Oxford Biomedica reiterates sales outlook but half-year loss widens

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.